Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
jardiance
boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - cukura diabēts - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 un 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.
Latvija -
latviešu -
Zāļu valsts aģentūra
empagliflozin polpharma 10 mg apvalkotās tabletes
zaklady farmaceutyczne polpharma s.a., poland - empagliflozīns - apvalkotā tablete - 10 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
empagliflozin polpharma 25 mg apvalkotās tabletes
zaklady farmaceutyczne polpharma s.a., poland - empagliflozīns - apvalkotā tablete - 25 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
glusod 10 mg apvalkotās tabletes
medochemie ltd., cyprus - empagliflozīns - apvalkotā tablete - 10 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
glusod 25 mg apvalkotās tabletes
medochemie ltd., cyprus - empagliflozīns - apvalkotā tablete - 25 mg